Oroxcell is an independent research organization (CRO) offering research services assessing the safety, toxicity and efficacy of active ingredients and finished formulations.
Specialized in in-vitro testing, particularly in 3D Human Models, Oroxcell is developing its business on two fronts:
• Safety & efficacy testing: From screening to GLP Compliant studies, we provide well established In-vitro platform, 2D and 3D models, for performing routine and regulatory safety testing, ADME (Absorption, Distribution, Metabolism, and Elimination) and Toxicity (sensitization, phototoxicity and genotoxicity) tests, bioanalytical studies, for evaluating pharmaceuticals, medical devices, cosmetics, nutraceuticals, home care and chemical products.
• Research & Innovation: Oroxcell provides a wide range of services including R&D project management and technical support, international consortium setup and management and regulatory & toxicology consulting.
We assist you in selecting or developing the best alternative testing methods for your safety and efficacy issues.
Oroxcell has been certified GLP compliant (Grade A, the highest grade) since 2011 by the French National Medicines and Cosmetics Safety Agency, ANSM.
Cerbios is a swiss privately held company specialized in the development and manufacturing of chemical and biological APIs for its world-wide partners.
The exclusive R&D and manufacturing expertise is available to our Pharma partners needing to develop and scale-up NCE or NBE for clinical trials, registration and commercial purpose.
cGMP APIs made by Cerbios in its FDA inspected site in Switzerland are sold worldwide mainly to pharma companies including EU, USA and Japan.
Cerbios is specialized in Reduced Folates (world leader position) but also in the manufacturing of High Potency Active Ingredients (HPAPIs) with a series of Vitamin D derivatives requiring sophisticated production units with high containment levels.
Another core business is the research, development and production of Probiotics of Pharma quality.
On top of that, in the last 17 years, CERBIOS has acquired a vast experience with Recombinant Proteins from mammalian cells (CHO) based on a state-of-the-art platform.
Service for third parties in exclusive manufacturing is concentrated in the area of HPAPI and Recombinant Proteins.
Full CMC support is given to our customers in order to provide them with the supply of cGMP clinical batches, registration/validation material and commercial manufacturing. Paramount to that is the supply of all documentation required for a successful registration.
Coris BioConcept is a leading expert in the field of immunochromatographic (IC) and oligochromatographic (OC) technologies. Based in Belgium and established in 1996 by Thierry Leclipteux (CEO), the company develops, produces and markets diagnostic kits, mainly for the detection of human respiratory and gastro-enteric infectious pathogens (bacteria, virus and parasites), and for the detection of antibiotic resistance markers (RESIST products). These rapid tests are extensively used in microbiology laboratories worldwide.
To complement this extensive range of fast and accurate lateral flow tests, the company has developed an innovative fully automated platform that performs multiplex PCR amplification and detection, on a microfluidic cartridge (TRAPIST products). This molecular
multiplex plateform allows syndromic diagnostic approach for the clinical management of main human infections like in sepsis, meningitidis, respiratory and enteric diseases.
Coris BioConcept is currently involved in multiple collaborative international projects (under Belgian and/or European grants) for the development of class-B metallo-betalactamase rapid IC tests, fast and unique nucleic acid extraction system from blood cultures, nanotechnology solution to fight against multi-drug resistant bacteria, and much more projects.
This R&D expertise is ideally suited for the “on-demand” production of innovative solutions in a rapidly changing world that calls for cutting edge biotechnology to take us forward into a healthy future.
All Coris BioConcept’s products fulfill the CE marking requirements and the company is also certified ISO 1 3485.
EDASA Scientific Limited is a Chemistry Contract Research Organization active in Organic Synthetic Chemistry.
Exclusive access to the best Russian brains and facilities.
A highly experienced and flexible approach.
EDASA delivers innovative compounds and creative solutions with considerable economies of cost and time.
EDASA Scientific provides solutions for:
Medicinal Chemistry Projects
Natural Product Synthesis
Synthetic Pathway Design & Optimization
Compound Isolation/Purification Services
Synthetic Scale up Work & API production
Chemical Waste Management
EDASA Scientific’s R&D site is based in Moscow State University’s (MSU) Science Park. As a result, EDASA Scientific has access to MSU’s facilities, as well as a broad range of scientific instruments for compound characterizations such as X-ray, bidimensional NMR, elementary analyzers, and HPLC. EDASA Scientific has access to talented MSU students and premium Russian scientists to be allocated for our collaborator‘s projects. We are also able to partner with MSU’s biological organizations for project follow-ups in biology.
Who are we?
Efarmes is a generic pharmaceutical company devoted to develop and manufacture generics for third parties all over the world. Efarmes Generics Company is part of Lacer Group. Our head offices, manufacturing site with EU cGMP’s and R&D area are in Barcelona.
What we do?
Efarmes Generics Company seeks partners that want to in-license and market the generics. Our partners are both multinational and local pharmaceutical companies on the five continents. Efarmes Generics Company offers tailored-made proposals such as full development and manufacturing of generic pharmaceutical products ready to be marketed by third parties under their own brand name, co-development of generic products, and contract manufacturing.
How we do it?
Efarmes Generics Company covers all levels from formulation to finished product delivery. Efarmes Generics Company currently supplies finished dosage forms to many key players all over the world. Our manufacturing site plant produced last year 24 M units (3.240 batches) with 99,9% Quality Control Conforming.
Our Business Proposal
Our main business model is the out license and supply of generic finished dosage forms. Our dossiers are in EU CTD format and ready to file. We have some MAs available in Europe.
Dossiers under development:
- Olmersartan + Amlodipine + Hidroclorothiazide (Hypertension). Q2 2016 Bioequivalence studies on-going.
- Tapentadol, retard tabs, (Neurophatic Pain). Dossier will be available in 2018.
Products which are subject to patent are currently not offered or made available in countries where patents are in force. No orders or deliveries prior to the expiry date of valid patents are possible.